A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer

Mette T. Faber, PhD, Kirsten Frederiksen, PhD, Joel M. Palefsky, MD, Susanne K. Kjaer, DMSc

Table of contents:
Supplementary Table 1:.................................................................................................................. 1
Supplementary Table 1: Hazard ratios (HR) with 95% confidence intervals (CI) of progression from AIN3 to anal squamous cell carcinoma (ASCC) among individuals at risk 6 months after AIN3 diagnosis 1995-2016 (Total number of person years = 9,452).

| Autoimmune disease | Number of person years | Number of ASCC cases | HR* (95% CI) | HR† (95% CI) |
|--------------------|------------------------|-----------------------|--------------|--------------|
| Never              | 8,833                  | 68                    | ref.         | ref.         |
| Yes, before AIN3   | 382                    | 5                     | 1.90 (0.76–4.78) | 1.81 (0.73–4.53) |
| Yes, only after AIN3 | 237                  | 5                     | 2.38 (0.93–6.11) | 2.89 (1.14–7.36) |

| Genital warts      |                         |                       |              |              |
|--------------------|------------------------|-----------------------|--------------|--------------|
| Never              | 6,119                  | 42                    | ref.         | ref.         |
| Yes, before AIN3   | 2,741                  | 30                    | 2.02 (1.20–3.40) | 2.12 (1.27–3.54) |
| Yes, only after AIN3 | 592                   | 6                     | 1.84 (0.76–4.48) | 1.87 (0.78–4.48) |

| HIV-status before AIN3 diagnosis | Number of person years | Number of ASCC cases | HR† (95% CI) | HR‡ (95% CI) |
|----------------------------------|------------------------|----------------------|--------------|--------------|
| Negative                         | 9,081                  | 67                   | ref.         | ref.         |
| Positive                         | 371                    | 11                   | 4.80 (2.06–11.2) | 5.36 (2.41–11.9) |
| CD4≥200 cells/µl                 | 273                    | ≥5                   | 3.68 (1.37–9.88) | 4.34 (1.71–11.0) |
| CD4<200 cells/µl                 | 74                     | <5                   | 8.47 (2.86–25.1) | 9.71 (3.31–28.5) |

*Adjusted for time since AIN3, age at AIN3, year of diagnosis, and sex.
†Adjusted for time since AIN3, age at AIN3, year of diagnosis, sex, and treatment of AIN3.
‡Due to missing values for CD4 count the numbers do not sum up to the total number of person years for HIV positive individuals